BMS and AstraZeneca settle dispute for $510m

03-08-2023

Marisa Woutersen

BMS and AstraZeneca settle dispute for $510m

Joint stipulations approved by federal judge to dismiss three lawsuits alleging patent infringement on cancer immunotherapies | Companies settle early ‘to save time and attention’ say reports.


Bristol Myers Squibb, AstraZeneca, patent, FiercePharma, Delaware

LSIPR